

**WEDNESDAY 12<sup>th</sup> NOVEMBER 2014 COMMENCING 9.30 AM**  
**AT THE PARK INN HOTEL CARDIFF NORTH, CIRCLE WAY EAST**  
**LLANEDEYRN, CARDIFF, CF23 9XF**

### **AGENDA**

- |    |                                    |                  |
|----|------------------------------------|------------------|
|    |                                    | <b>Enclosure</b> |
| 1. | <b>Welcome and introduction</b>    |                  |
| 2. | <b>Apologies</b>                   |                  |
| 3. | <b>Declarations of interest</b>    |                  |
| 4. | <b>Minutes of previous meeting</b> | 1/AWMSG/1114     |

***To protect commercial confidentiality, the first appraisal will be conducted in private.***  
***The meeting will open to the public at approx 10.15am***

- |    |  |              |
|----|--|--------------|
|    |  | 2/AWMSG/1114 |
| 5. | <b>Appraisal 1 – Full Submission (WPAS)</b>  | Appendices   |
|    | <b>Rituximab (MabThera<sup>®</sup>)</b> for the treatment of non-Hodgkin's lymphoma: treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy; maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy; and treatment of patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy |              |

***The meeting will now open to the public***

- |    |  |              |
|----|--|--------------|
|    |  |              |
| 6. | <b>Chairman's report (verbal update)</b>   |              |
| 7. | <b>Appraisal 2 - Full Submission</b>   | 3/AWMSG/1114 |
|    | <b>Umeclidinium bromide (Incruse<sup>®</sup>)</b> for maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease  | Appendices   |
| 8. | <b>Appraisal 3 - Full Submission</b>   | 4/AWMSG/1114 |
|    | <b>Olodaterol hydrochloride (Striverdi<sup>®</sup> Respimat<sup>®</sup>)</b> for maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease | Appendices   |
| 9. | <b>Feedback from AWPAG meeting 24<sup>th</sup> September 2014</b>  | 5/AWMSG/1114 |

- |   |                            |
|---|----------------------------|
| 10. <b>Appraisal 4 - Full Submission</b><br><b>Ponatinib (Iclusig®)</b> for the treatment of adult patients with: chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation; or Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation | 6/AWMSG/1114<br>Appendices |
| 11. <b>Appraisal 5 - Limited Submission</b><br><b>Leuprorelin acetate (Prostap® 3 DCS/SR DCS)</b> as neoadjuvant treatment prior to radiotherapy in patients with high risk localised or locally advanced prostate cancer   | 7/AWMSG/1114<br>Appendices |
| 12. <b>Revised AWMSG Constitution</b>   | 8/AWMSG/1114               |

**Date of next meeting:**  
**Wednesday 17<sup>th</sup> December 2014 in Abergavenny**